Flash Therapeutics is a French CDMO and expert in lentiviral vector production. The company leverages its proprietary lentiviral platform and bioproduction technologies to help produce novel CGT therapies. By providing efficient, transient, and short-term RNA delivery technology, their LentiFlash® technology is suitable for gene editing and other advanced therapeutic approaches. Flash Therapeutics was formed in 2018 through the merger of FlashCell and Vectalys — two privately held CGT companies.